PMID- 9391292
OWN - NLM
STAT- MEDLINE
DCOM- 19971217
LR  - 20190503
IS  - 1355-6037 (Print)
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 78
IP  - 3
DP  - 1997 Sep
TI  - Comparison of captopril and ibopamine in mild to moderate heart failure.
PG  - 285-90
AB  - OBJECTIVE: To determine the effects of ibopamine 100 mg three times daily 
      compared with captopril 25 mg three times daily on exercise capacity in patients 
      with chronic heart failure. DESIGN: A randomised, double blind, parallel group 
      comparison of the addition of ibopamine versus captopril during a period of 24 
      weeks. SETTING: 26 outpatient cardiology clinics in seven European countries. 
      PATIENTS: 266 patients, with mild to moderate chronic heart failure (New York 
      Heart Association (NYHA) functional class II, 81% and III, 19%) and evidence of 
      an enlarged left ventricle. Patients received concomitant treatment with 
      diuretics and/or digitalis. MAIN OUTCOME MEASURE: Exercise duration after 24 
      weeks of treatment, compared with baseline. RESULTS: Mean (SD) ejection fraction 
      was 29 (8)% and the baseline exercise duration in the captopril and ibopamine 
      groups 665 (160) and 675 (174) seconds, respectively. At the end of the study, 
      exercise duration had improved in both groups, by 29 seconds in the ibopamine 
      group (P < 0.01), and by 24 seconds in the captopril group (P < 0.05). There was 
      no difference between groups (P = 0.69, 95% confidence interval -22 to 33). NYHA 
      class, signs and symptoms score, and dyspnoea and fatigue index improved equally 
      in both groups. The total number of adverse events was the same in both treatment 
      groups, but gastrointestinal complaints occurred more often in the ibopamine 
      group. The number of patients with premature withdrawals was no different. 
      CONCLUSIONS: No difference was detected between the effect of captopril and 
      ibopamine on exercise time in patients with mild to moderate heart failure during 
      a treatment period of 24 weeks.
FAU - Dohmen, H J
AU  - Dohmen HJ
AD  - Department of Cardiology, Bosch Medicentrum, 's-Hertogenbosch, The Netherlands.
FAU - Dunselman, P H
AU  - Dunselman PH
FAU - Poole-Wilson, P A
AU  - Poole-Wilson PA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Dopamine Agonists)
RN  - 8ZCA2I2L11 (ibopamine)
RN  - 9G64RSX1XD (Captopril)
RN  - R7339QLN1C (Deoxyepinephrine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/therapeutic use
MH  - Captopril/*administration & dosage/therapeutic use
MH  - Deoxyepinephrine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Dopamine Agonists/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
PMC - PMC484932
EDAT- 1997/12/10 00:00
MHDA- 1997/12/10 00:01
PMCR- 2000/09/01
CRDT- 1997/12/10 00:00
PHST- 1997/12/10 00:00 [pubmed]
PHST- 1997/12/10 00:01 [medline]
PHST- 1997/12/10 00:00 [entrez]
PHST- 2000/09/01 00:00 [pmc-release]
AID - 10.1136/hrt.78.3.285 [doi]
PST - ppublish
SO  - Heart. 1997 Sep;78(3):285-90. doi: 10.1136/hrt.78.3.285.